WO2002022855A2 - Test-strips with positively charged membranes for tetrazolium based assays - Google Patents
Test-strips with positively charged membranes for tetrazolium based assays Download PDFInfo
- Publication number
- WO2002022855A2 WO2002022855A2 PCT/US2001/028169 US0128169W WO0222855A2 WO 2002022855 A2 WO2002022855 A2 WO 2002022855A2 US 0128169 W US0128169 W US 0128169W WO 0222855 A2 WO0222855 A2 WO 0222855A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analyte
- signal producing
- producing system
- positively charged
- water soluble
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/521—Single-layer analytical elements
- G01N33/523—Single-layer analytical elements the element being adapted for a specific analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Definitions
- Analyte measurement in physiological fluids is of ever increasing importance to today's society.
- Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions.
- Analytes of interest include alcohol, formaldehyde, glucose, glutamic acid, glycerol, beta-hydroxybutyrate, L-lactate, leucine, malic acid, pyruvic acid, steroids, etc.
- analyte measurement protocols and devices for both clinical and home use have been developed.
- Patent documents of interest include: EP 0 908 453 Al; WO 94/01578 and WO
- test strips and methods for their use in the detection of an analyte in a sample are provided.
- the subject test strips are characterized by at least including a water soluble tetrazolium salt on a surface of a positively charged substrate.
- the water soluble tetrazolium salt is present as part of an analyte oxidizing signal producing system, which system includes one or more of the following additional components: an analyte oxidizing enzyme, e.g., an analyte dehydrogenase or an analyte oxidase; an electron transfer agent; and an enzyme cofactor.
- systems and kits incorporating the subject test strips.
- the subject test strips, systems and kits find use in the measurement of a wide variety of analytes in a sample, such as a physiological sample, e.g., blood or a fraction thereof, or ISF (interstitial fluid).
- FIGURES Figure 1 provides the results of a 400mg/dl Glucose Test conducted on positively charged and non-charged membranes, using water soluble tetrazolium as indicator according to the subject invention.
- test strips and methods for their use in the measurement of an analyte in a sample are provided.
- the subject test strips are characterized by at least including a water soluble tetrazolium salt on a surface of a positively charged substrate.
- the water soluble tetrazolium salt is present as part of an analyte oxidizing signal producing system, which system includes one or more of the following additional components: an analyte oxidizing enzyme, e.g., an analyte dehydrogenase or an analyte oxidase; an electron transfer agent; and an enzyme cofactor.
- systems and kits incorporating the subject test strips.
- the subject test strips, systems and kits find use in the detection of a wide variety of analytes in a sample, such as a physiological sample, e.g., blood or a fraction thereof, or ISF (interstitial fluid).
- the subject invention provides compositions for use in detecting a wide variety of analytes in a sample.
- the compositions include a positively charged substrate and water soluble tetrazolium salt present on the surface of the substrate, typically as a member of an analyte oxidizing signal producing system.
- the subject compositions are typically present as dry compositions, such as are found in reagent test strips.
- the invention provides strips for assaying for a particular analyte in whole blood or a derivative fraction thereof, e.g., glucose, alcohol, glycated proteins, etc.
- the reagent test strips include a positively charged substrate and an analyte oxidizing signal producing system present on a surface of the substrate, which system includes a water soluble tetrazolium salt.
- a feature of the subject compositions is the presence of a positively charged substrate.
- positively charged substrate is meant a substrate that displays one or more, usually a large plurality of, positive charges, e.g., as found on positively charged groups or moieties, on at least one of its surfaces.
- the substrate may be fabricated from a single material or may be a composite of two or more different materials, where these different materials may be blended, layered, or otherwise arranged to provide for the desired positively charged surface.
- the positively charged substrate may be bibulous or non-bibulous.
- bibulous is meant a material that exhibits preferential retention of one or more components as would occur, for example, in materials capable of absorbing or "imbibing" one or more components, as occurs in chromatographic separations. Examples of bibulous materials include, but are not limited to: untreated forms of paper, nitrocellulose and the like which result in chromatographic separation of components contained in liquids which are passed therethrough.
- the positively charged substrate may be non-bibulous.
- Non- bibulous positively charged substrate include inert porous matrices which provide a support for the various members of the signal producing system, described infra, and have a positive charge.
- These matrices are generally configured to provide a location for application of a physiological sample, e.g., blood, and detection of the chromogenic product produced by the dye of the signal producing system.
- the matrix is typically one that is permissive of aqueous fluid flow through it and provides sufficient void space for the chemical reactions of the signal producing system to take place.
- a number of different positively charged porous matrices have been developed for use in various analyte measurement assays, which matrices may differ in terms of materials, pore sizes, dimensions and the like, where representative matrices include those described in U.S.
- the dimensions and porosity of the test strip may vary greatly, where the matrix may or may not have a porosity gradient, e.g., with larger pores near or at the sample application region and smaller pores at the detection region.
- Positively charged membranes can be prepared by using positively charged polymers, such as polyamide.
- such membranes can be prepared by various techniques, such as surface coating using cationic surfactants or polymers.
- the coating can be applied by dip coating, chemical treatment, photografting, plasma polymerization, etc.
- the membrane can be prepared by means of blending one or more positively charged materials with the membrane forming polymer.
- positively charged polymers are polyamide, poly(vinyl pyridine), poly(vinyl imidazole), poly(allylamine), poly(vinyl benzyldimethyl ammonium chloride), polylysine and chitosan.
- cationic surfactants include those containing primary, secondary and quaternary amino groups.
- the material may or may not be functionalized to provide for covalent or noncovalent attachment of the various members of the signal producing system, described in greater detail infra.
- the matrix is configured as a membrane test pad and is affixed to a solid support, where the support may be a plastic (e.g., polystyrene, nylon or polyester) or metallic sheet or any other suitable material known in the art.
- a plastic e.g., polystyrene, nylon or polyester
- metallic sheet e.g., metallic sheet
- a feature of the subject compositions is that they include at least one water soluble tetrazolium salt, which component is typically present in conjunction with one or more members of an analyte oxidizing signal producing system.
- a feature of the subject compositions is the presence of a water soluble tetrazolium salt that is capable of accepting a hydride to product a water soluble, colored formazan product.
- Water soluble tetrazolium salts of interest include those described in EP 0 908 453, the disclosure of which is herein incorporated by reference.
- One class of water soluble tetrazolium salts of interest include those described by formula 2 on page 2, lines 35 to 48 of EP 0 908 453.
- Another class of water soluble tetrazolium salts of interest include those described by formula 1 on page 3, lines 10-25 of EP 0 908 453.
- Specific water soluble tetrazolium compounds or salts that are of particular interest include, but are not limited to: 2,2'-dibenzothiazo ⁇ yl-5,5'-bis[4-di(2- sulfoethyl)carbamoylphenyl]-3,3 '-(3,3 '-dimethoxy- 4,4'-biphenylene)ditetrazolium, disodium salt (WST-5); 2-benzothiazolyl-3-(4-carboxy-2-methoxyphenyl)-5-[4-(2- sulfoethylcarbamoyl)phenyl]-2H-tetrazolium (WST-4) and the like.
- WST-5 is preferred in many embodiments because it readily dissolves in an aqueous medium, which is most compatible with biological samples. Furthermore, the resulting formazan compound exhibits strong spectral absorption at the purple-blue region, thus reducing the need for correcting the background signal from hemoglobin.
- the water soluble tetrazolium salt is typically present as a member of an analyte oxidizing signal producing system.
- signal producing system is meant a collection of two or more compounds or molecules which are capable of acting in concert, when combined, to produce a detectable signal that is indicative of the presence of, and often amount of, a particular analyte in a given sample.
- the term signal producing system is used broadly to encompass both a mixture of all of the reagent constituents of the signal producing system as well as a system in which one or more of the reagent constituents are separated from the remainder of the reagent constituents, e.g., as is present in a kit.
- the signal producing system of the subject compositions and test strips is a analyte oxidizing signal producing system.
- the analyte oxidizing agent is generally an enzyme that is capable of removing a hydride from the analyte of interest to produce an oxidized form of the analyte.
- Analyte oxidizing enzymes of interest include analyte oxidases and analyte dehydrogenases.
- Analyte oxidases of interest include, but are not limited to: glucose oxidase (where the analyte is glucose); cholesterol oxidase (where the analyte is cholesterol); alcohol oxidase (where the analyte is alcohol); bilirubin oxidase (where the analyte is bilirubin); choline oxidase (where the analyte is choline); formaldehyde dehydrogenase (where the analyte is formaldehyde); glutamate oxidase (where the analyte is L-glutamic acid); glycerol oxidase (where the analyte is glycerol); galactose oxidase (where the analyte is galactose); L-ascorbate oxidase (where the analyte is ascorbic acid); lactate oxidase (where the analy
- Analyte dehydrogenases of interest include, but are not limited to: alcohol dehydrogenase for alcohol; formaldehyde dehydrogenase for formaldehyde; glucose dehydrogenase for glucose; glucose-6-phosphate dehydrogenase for glucose-6- phosphate; glutamate dehydrogenase for glutamic acid; glycerol dehydrogenase for glycerol; beta-hydroxybutyrate dehydrogenase for beta-hydroxybutyrate; hydroxysteroid dehydrogenase for steroid; L-lactate dehydrogenase for L-lactate; leucine dehydrogenase for leucine; malate dehydrogenase for malic acid, and pyruvate dehydrogenase for pyruvic acid.
- the subject signal producing systems also include an enzyme cofactor that is capable of interacting with the oxidizing agent in a manner such that the analyte of interest is oxidized by the oxidizing agent, which agent concomitantly reduces the enzyme cofactor.
- Enzyme cofactors of interest include, but are not limited to: i.e., beta-nicotinamide adenine dinucleotide (beta-NAD); beta- nicotinamide adenine dinucleotide phosphate (beta-NADP); thionicotinamide adenine dinucleotide; thionicotinamide adenine dinucleotide phosphate; nicotinamide 1,N6- ethenoadenine dinucleotide; nicotinamide 1 ,N6-ethenoadenine dinucleotide phosphate; and pyrrolo-quinoline quinone (PQQ).
- beta-nicotinamide adenine dinucleotide beta-NAD
- beta-NADP beta- nicotinamide adenine dinucleotide phosphate
- Enzyme cofactors of particular interest that may be included in the subject signal producing systems include: NADH or NAD(P)H.
- the subject signal producing systems typically include an electron transfer agent.
- electron transfer agent is meant a compound or molecule that can transfer an electron, in the form of a hydride ion, from a reduced enzyme cofactor to the water soluble tetrazolium product.
- Electron transfer agents of interest include both low and high molecular weight electron transfer agents. In this specification, low molecular weight means a molecular weight that does not exceed about 2000 daltons, usually about 1000 daltons and in many embodiments about 500 daltons.
- High molecular weight means a molecular weight of at least about 5000 daltons and in many embodiments 10,000 or 20,000 daltons or higher. The molecular weight of the high molecular weight electron transfer agent often will not exceed about 100,000 daltons.
- the low molecular weight electron transfer agent is a non-proteinaceous compound while the high molecular weight electron transfer agent is a proteinaceous compound.
- proteinaceous is meant a polypeptide or polymeric mimetic thereof.
- a variety of low molecular weight non-proteinaceous electron transfer agents are of interest. These agents include: flavins such as riboflavin (RBF), alloxazine (ALL) and lumichrome (LC); phenazines such as phenazine, phenazine methosulfate
- PMS phenazine ethosulfate, methoxyphenazine methosulfate and safranine
- methyl- 1, 4-naphthol (menadione) phenothiazines such as PT and its radical cation, PT+, thionin (TH), azure A (AA), azure B (AB), azure C (AC), methylene blue (MB), methylene green (MG) and toluidine blue O (TOL); phenoxazines such as phenoxazine (POA), basic blue 3 (BB3), and brilliant cresyl blue ALD (BCBA), benzo- ⁇ -phenazoxonium chloride (Medola's blue); Indophenols such as 2,6- dichlorophenol indophenol (DCIP); and Indamines such as Bindschedler's green and phenylene blue; and the like.
- phenoxazines such as phenoxazine (
- phenazine compounds e.g. PMS, phenazine ethosulfate, methoxyphenazine methosulfate and safranine
- PMS is the low molecular weight, non- proteinaceous electron transfer agent in many embodiments.
- the high molecular weight proteinaceous electron transfer agent is an enzyme that is capable of oxidizing a reduced cofactor, e.g. NAD(P)H, and concomitantly reducing the tetrazololium salt of the signal producing system.
- this electron transfer enzyme is a diaphorase, such as lipoic dehydrogenase, ferredoxin-NADP reductase, lipoamide dehydrogenase, NADPH dehydrogenase, etc.
- diaphorases A variety of diaphorases are available and may be employed, where representative commercially available diaphorases that may be present in the subject signal producing systems include bacillus diaphorase, clostridium diaphorase, vibrio diaphorase, porcine diaphorase, and the like.
- the signal producing systems described above are generally present in the subject compositions as reagent compositions.
- the reagent compositions are dry compositions.
- the subject reagent compositions are ones that include the water soluble tetrazolium salt.
- the reagent compositions further include an enzyme cofactor, an analyte oxidizing enzyme and an electron transfer agent, where these components are described above.
- reagent test strips that include the above described compositions and are intended for use in measuring the presence or concentration of an analyte in a sample.
- the invention provides dry strips for assaying for a particular analyte in whole blood, e.g., beta-hydroxybutyrate, glucose, etc.
- the reagent test strip includes a positively charged solid support and a dry reagent composition present thereon, where the dry reagent composition is made up of all of the reagent compounds necessary to produce a detectable signal in the presence of the analyte of interest.
- the dry reagent composition present on the subject test strip is one that includes the following members: an analyte oxidizing enzyme, an enzyme cofactor, an electron transfer agent and a water soluble tetrazolium salt, where each of these constituent members are described in greater detail above.
- the subject test strips include a membrane test pad that is affixed to a solid support.
- the support may be a plastic ⁇ e.g., polystyrene, nylon, or polyester - or metallic sheet or any other suitable material known in the art.
- the reagent composition Associated with the test pad, e.g., coated onto the test pad, incorporated into the test pad, etc., is the reagent composition.
- the strip may also be configured in more complex arrangements, e.g., where the test pad is present between the support and a surface layer, where one or more reagents employed in sample processing may be present on the surface layer.
- flow paths or channels may be present on the test strip, as is known in the art.
- the subject test strips may be fabricated employing any convenient protocol.
- One convenient protocol is to contact at least the test pad portion of the strip with an aqueous composition that includes all of the members of the reagent composition that is to be associated with the test pad in the final reagent test strip.
- the test pad may be immersed in the aqueous composition, maintained therein for a sufficient period of time and then dried, whereby the test pad of the reagent test strip which has associated therewith the reagent composition is produced.
- the aqueous composition will include the various members of the reagent composition to be associated with the test pad of the reagent test strip, where the various members are present in amounts sufficient to provide for the desired amounts in the reagent composition that is produced on the test pad.
- the concentration of electron transfer agent present in this aqueous composition typically ranges from about 10 to 50,000, usually from about 50 to 10,000 and more usually from about 100 to 5,000 ⁇ M.
- the concentration of the electron transfer agent present in the aqueous composition typically ranges from about 10 to 10,000, usually from about 50 to 5,000 and more usually from about 100 to 3,000 U/ml.
- the concentration of tetrazolium salt present in the aqueous composition ranges from about 3 mM to 36 mM, usually from about 6 mM to 24mM.
- the enzyme cofactor ranges in concentration from about 1.5 mM to 28 mM, usually from about 3.5mM to 14 mM.
- the analyte oxidizing agent enzyme ranges in concentration from about 100 U to 2000 U, and usually from about 200 U to 1000 U when present. See the experimental section, infra, for a more detailed description of a representative method for preparing the subject reagent test strips.
- the above described signal producing systems, reagent compositions and test strips find use in methods of detecting the presence of, and often the amount of, i.e., the concentration of, an analyte in a sample.
- a variety of different analytes may be detected using the subject methods, where representative analytes include those described above, e.g., alcohol, formaldehyde, glucose, glutamic acid, glycerol, beta- hydroxybutyrate, L-lactate, leucine, malic acid, pyruvic acid, steroids, etc.
- the subject methods may be used to determine the presence, and often concentration, of an analyte in a variety of different physiological samples, such as urine, tears, saliva, and the like, they are particularly suited for use in determining the concentration of an analyte in blood or blood fractions, e.g., blood derived samples, and more particularly in whole blood, ISF (interstitial fluid).
- blood or blood fractions e.g., blood derived samples, and more particularly in whole blood, ISF (interstitial fluid).
- the sample and the signal producing system are combined into a reaction mixture, the reaction is allowed to proceed for a sufficient period to time to generate a signal indicative of the presence of (and often amount of) analyte in the sample, and the resultant signal is detected and related to the presence of (and often amount of) analyte in the sample.
- the above steps take place on a reagent test strip as described supra.
- a feature of the subject methods is that the detectable signal is made up of a non- washable spot that forms on the surface of the substrate of the strip.
- the non- washable spot is made up of water soluble formazan product which is tightly bound to the substrate surface such that it cannot be readily removed from the surface under standard washing conditions.
- standard washing conditions is meant the conditions experienced by substrate surface in analyte detection assays where unbound component has to be removed from the surface.
- An example of standard washing conditions are those employed by those of skill in the art in array based nucleic acid hybridization assays, where non-hybridized nucleic acids are removed from the surface of an array following a hybridization step. Such conditions are well known to those of skill in the art.
- a feature of the subject methods is the production of a non- washable spot on the surface of the positively charged substrate, where the non- washable spot is made up of the water soluble formazan product.
- the first step is to apply a quantity of the physiological sample to the test strip, where the test strip is described supra.
- the amount of physiological sample, e.g. blood, that is applied to the test strip may vary, but generally ranges from about 2 ⁇ L to 40 ⁇ L, usually from about 5 ⁇ L to 20 ⁇ L.
- the blood sample size that is applied to the test strip may be relatively small, ranging in size from about 2 ⁇ L to 40 ⁇ L, usually from about 5 ⁇ L to 20 ⁇ L.
- blood samples of a variety of different hematocrits may be assayed with the subject methods, where the hematocrit may range from about 20% to 65%, usually from about 25% to 60%.
- the sample is allowed to react with the members of the signal producing system to produce a detectable product, i.e., the non-washable spot, that is present in an amount proportional to the initial amount of the analyte of interest present in the sample.
- the amount of detectable product i.e., signal produced by the signal producing system in the form of the non- washable spot, is then determined and related to the amount of analyte in the initial sample.
- automated instruments that perform the above mentioned detection and relation steps are employed. The above described reaction, detection and relating steps, as well as instruments for performing the same, are further described in U.S. Patent Nos.
- kits for use in practicing the subject methods at least include a signal producing system as described above, where the signal producing system components may be combined into a single reagent composition or separated, e.g., present in separate containers. In certain embodiments, the signal producing system will be present in the kits in the form of a reagent test strip, as described supra.
- the subject kits may further include a means for obtaining a physiological sample. For example, where the physiological sample is blood, the subject kits may further include a means for obtaining a blood sample, such as a lance for sticking a finger, a lance actuation means, and the like.
- the subject kits may include a control solution or standard, e.g.
- kits also include an automated instrument, as described above, for detecting the amount of product produced on the strip following sample application and relating the detected product to the amount of analyte in the sample.
- kits include instructions for using the subject kit components in the determination of an analyte concentration in a physiological sample. These instructions may be present on one or more of the packaging, a label insert, containers present in the kits, and the like.
- a 0.8 ⁇ m nylon membrane obtained from Pall Corporation (East Hills, NY) was dipped into the reagent of Table 1, until saturated. The excess reagent was scraped off gently with a glass rod. The resulting membrane was hung to dry in a 56° C oven for 10 minutes. Porex (0.6 mm thick) was soaked in the nitrite solution of Table 2 and then hung to dry in a 100° C oven for ten hours. Finally, the membrane was laminated between a polyester stock (0.4 mm Melenex® polyester from ICI America, Wilmington, DE) and the nitrite-impregnated Porex.
- Example 1 The procedure of Example 1 was repeated, except that the first dip was the reagent of Table 3, and there was no second dip, since the Porex was not needed.
- the coated membrane was tested by 400mg/dl glucose.
- the subject invention provides for improvement over previous reagent test strip formats.
- the subject invention is the beneficiary of all of the positive attributes of tetrazolium compounds and is able to produce a non- washable reporter signal from the resultant water soluble formazan product.
- the subject invention represents a significant contribution to the art.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-7003589A KR20030065475A (en) | 2000-09-12 | 2001-09-07 | Test strips with positively charged membranes for tetrazolium based assays |
AT01968705T ATE310832T1 (en) | 2000-09-12 | 2001-09-07 | TEST STRIPS WITH POSITIVELY CHARGED MEMBRANES FOR TETRAZOLIUM BASED ASSAY |
JP2002527297A JP2004509618A (en) | 2000-09-12 | 2001-09-07 | Test strip for detecting the presence of reduced cofactors in a sample and methods of use thereof |
IL15471301A IL154713A0 (en) | 2000-09-12 | 2001-09-07 | Test strips for detecting the presence of a reduced cofactor in a sample and methods for using the same |
AU8893501A AU8893501A (en) | 2000-09-12 | 2001-09-07 | Test strips for detecting the presence of a reduced cofactor in a sample and methods for using the same |
CA002422010A CA2422010A1 (en) | 2000-09-12 | 2001-09-07 | Test strips for detecting the presence of a reduced cofactor in a sample and methods for using the same |
EP01968705A EP1317563B1 (en) | 2000-09-12 | 2001-09-07 | Test-strips with positively charged membranes for tetrazolium based assays |
DE60115261T DE60115261T2 (en) | 2000-09-12 | 2001-09-07 | TEST STRIPS WITH POSITIVE-LOADED MEMBRANES FOR TETRAZOLIUM BASED ASSAYS |
MXPA03002078A MXPA03002078A (en) | 2000-09-12 | 2001-09-07 | Test-strips with positively charged membranes for tetrazolium based assays. |
NO20031116A NO20031116L (en) | 2000-09-12 | 2003-03-11 | Test strips for detecting the presence of a reduced cofactor in a sample and methods for using them |
HK03106177A HK1053856A1 (en) | 2000-09-12 | 2003-08-28 | Test-strips with positively charged membranes for tetrazolium based assays |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/659,938 US6420128B1 (en) | 2000-09-12 | 2000-09-12 | Test strips for detecting the presence of a reduced cofactor in a sample and method for using the same |
US09/659,938 | 2000-09-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002022855A2 true WO2002022855A2 (en) | 2002-03-21 |
WO2002022855A3 WO2002022855A3 (en) | 2002-07-18 |
Family
ID=24647453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/028169 WO2002022855A2 (en) | 2000-09-12 | 2001-09-07 | Test-strips with positively charged membranes for tetrazolium based assays |
Country Status (21)
Country | Link |
---|---|
US (2) | US6420128B1 (en) |
EP (1) | EP1317563B1 (en) |
JP (1) | JP2004509618A (en) |
KR (1) | KR20030065475A (en) |
CN (1) | CN1561397A (en) |
AR (1) | AR030650A1 (en) |
AT (1) | ATE310832T1 (en) |
AU (1) | AU8893501A (en) |
CA (1) | CA2422010A1 (en) |
CZ (1) | CZ2003705A3 (en) |
DE (1) | DE60115261T2 (en) |
DK (1) | DK1317563T3 (en) |
ES (1) | ES2250472T3 (en) |
HK (1) | HK1053856A1 (en) |
IL (1) | IL154713A0 (en) |
MX (1) | MXPA03002078A (en) |
MY (1) | MY119106A (en) |
NO (1) | NO20031116L (en) |
PL (1) | PL363222A1 (en) |
RU (1) | RU2288273C2 (en) |
WO (1) | WO2002022855A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7727467B2 (en) | 2003-06-20 | 2010-06-01 | Roche Diagnostics Operations, Inc. | Reagent stripe for test strip |
US8071030B2 (en) | 2003-06-20 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Test strip with flared sample receiving chamber |
US8287703B2 (en) | 1999-10-04 | 2012-10-16 | Roche Diagnostics Operations, Inc. | Biosensor and method of making |
US8298828B2 (en) | 2003-06-20 | 2012-10-30 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
WO2013016200A1 (en) * | 2011-07-22 | 2013-01-31 | Access Bio, Inc. | A single-pad strip for an improved lateral flow assay and a test device using the same |
US8663442B2 (en) | 2003-06-20 | 2014-03-04 | Roche Diagnostics Operations, Inc. | System and method for analyte measurement using dose sufficiency electrodes |
US9410915B2 (en) | 2004-06-18 | 2016-08-09 | Roche Operations Ltd. | System and method for quality assurance of a biosensor test strip |
WO2018101525A1 (en) * | 2016-12-02 | 2018-06-07 | 에스디 바이오센서 주식회사 | Strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, manufacturing method therefor, and application thereof |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071384B2 (en) | 1997-12-22 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Control and calibration solutions and methods for their use |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US6656697B1 (en) * | 1998-09-28 | 2003-12-02 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
US6420128B1 (en) * | 2000-09-12 | 2002-07-16 | Lifescan, Inc. | Test strips for detecting the presence of a reduced cofactor in a sample and method for using the same |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
ATE485766T1 (en) | 2001-06-12 | 2010-11-15 | Pelikan Technologies Inc | ELECTRICAL ACTUATING ELEMENT FOR A LANCET |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
DE60234598D1 (en) | 2001-06-12 | 2010-01-14 | Pelikan Technologies Inc | SELF-OPTIMIZING LANZET DEVICE WITH ADAPTANT FOR TEMPORAL FLUCTUATIONS OF SKIN PROPERTIES |
US7749174B2 (en) | 2001-06-12 | 2010-07-06 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US6586199B2 (en) * | 2001-11-20 | 2003-07-01 | Lifescan, Inc. | Stabilized tetrazolium reagent compositions and methods for using the same |
US6837171B1 (en) | 2002-04-29 | 2005-01-04 | Palmer/Snyder Furniture Company | Lightweight table with unitized table top |
US20030119203A1 (en) * | 2001-12-24 | 2003-06-26 | Kimberly-Clark Worldwide, Inc. | Lateral flow assay devices and methods for conducting assays |
US6762035B1 (en) * | 2002-02-04 | 2004-07-13 | Surendra K. Gupta | Method and test strips for the measurement of fat loss during weight loss programs |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7892185B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US6847451B2 (en) * | 2002-05-01 | 2005-01-25 | Lifescan, Inc. | Apparatuses and methods for analyte concentration determination |
US7244394B2 (en) * | 2002-10-03 | 2007-07-17 | Novartis Ag | Methods and kits for assays of analytes of interest in tears |
US7781172B2 (en) | 2003-11-21 | 2010-08-24 | Kimberly-Clark Worldwide, Inc. | Method for extending the dynamic detection range of assay devices |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US20040214345A1 (en) * | 2003-04-23 | 2004-10-28 | Matzinger David P. | Ambidextrous capillary-filled test strip |
EP1628567B1 (en) | 2003-05-30 | 2010-08-04 | Pelikan Technologies Inc. | Method and apparatus for fluid injection |
DK1633235T3 (en) | 2003-06-06 | 2014-08-18 | Sanofi Aventis Deutschland | Apparatus for sampling body fluid and detecting analyte |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US7645373B2 (en) | 2003-06-20 | 2010-01-12 | Roche Diagnostic Operations, Inc. | System and method for coding information on a biosensor test strip |
US8058077B2 (en) | 2003-06-20 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Method for coding information on a biosensor test strip |
US8679853B2 (en) | 2003-06-20 | 2014-03-25 | Roche Diagnostics Operations, Inc. | Biosensor with laser-sealed capillary space and method of making |
US7645421B2 (en) | 2003-06-20 | 2010-01-12 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
US8206565B2 (en) | 2003-06-20 | 2012-06-26 | Roche Diagnostics Operation, Inc. | System and method for coding information on a biosensor test strip |
US7488601B2 (en) | 2003-06-20 | 2009-02-10 | Roche Diagnostic Operations, Inc. | System and method for determining an abused sensor during analyte measurement |
US7718439B2 (en) | 2003-06-20 | 2010-05-18 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
EP1680014A4 (en) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | Method and apparatus for a variable user interface |
US7943395B2 (en) | 2003-11-21 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Extension of the dynamic detection range of assay devices |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
EP1706026B1 (en) | 2003-12-31 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Method and apparatus for improving fluidic flow and sample capture |
EP1713926B1 (en) | 2004-02-06 | 2012-08-01 | Bayer HealthCare, LLC | Oxidizable species as an internal reference for biosensors and method of use |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
KR101321296B1 (en) | 2005-07-20 | 2013-10-28 | 바이엘 헬스케어 엘엘씨 | Gated amperometry temperature determination |
JP5671205B2 (en) | 2005-09-30 | 2015-02-18 | バイエル・ヘルスケア・エルエルシー | Gated voltammetry |
US20080003629A1 (en) * | 2006-04-07 | 2008-01-03 | Morris Shayne K | Device and method for detection of vitamins and nutritional minerals |
EP1936362B1 (en) * | 2006-12-20 | 2020-03-18 | Roche Diabetes Care GmbH | Test element with referencing |
EP2365968B1 (en) | 2007-09-29 | 2018-08-22 | Timothy James Williams | Composition and method to modify sperm function and increase male gender ratio in mammals |
WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
US20090219509A1 (en) * | 2008-02-29 | 2009-09-03 | Hiroshi Nomura | Optical sensor with enhanced reflectance |
US8008068B2 (en) * | 2008-02-29 | 2011-08-30 | Light Pointe Medical, Inc. | Nonhemolytic optical sensor with enhanced reflectance |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
KR20180004027A (en) * | 2016-06-30 | 2018-01-10 | 휴마시스 주식회사 | Analytical kit for enzyme activity |
CN109574296B (en) * | 2018-11-27 | 2021-05-07 | 合肥工业大学 | Method for recovering protein from crab meat protein-containing wastewater |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5902731A (en) * | 1998-09-28 | 1999-05-11 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3791988A (en) * | 1972-03-23 | 1974-02-12 | Hoffmann La Roche | Diagnostic test for glucose |
CS164231B2 (en) * | 1972-09-28 | 1975-11-07 | ||
FR2258235B1 (en) * | 1974-01-21 | 1981-02-06 | Voest Ag | |
US4254222A (en) * | 1978-07-19 | 1981-03-03 | Owen Oliver E | Semi-quantitative assay of lactic acid and β-hydroxy butyrate |
JPS6024199A (en) * | 1983-07-18 | 1985-02-06 | Nippon Chemiphar Co Ltd | Determination of substance relating to disease |
US5032506A (en) * | 1986-12-16 | 1991-07-16 | Enzymatics, Inc. | Color control system |
DE3826922A1 (en) * | 1988-08-09 | 1990-02-22 | Boehringer Mannheim Gmbh | PROCESS FOR THE COLOR-RIMETRIC DETERMINATION OF AN ANALYTE BY ENZYMATIC OXIDATION |
US5340722A (en) * | 1988-08-24 | 1994-08-23 | Avl Medical Instruments Ag | Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method |
SE466158B (en) * | 1989-04-25 | 1992-01-07 | Migrata Uk Ltd | METHOD OF ANALYSIS FOR GLUCOSE DETERMINATION IN WHOLE BLOOD |
WO1994001578A1 (en) | 1992-07-02 | 1994-01-20 | Boehringer Mannheim Corporation | Stabilizing tetrazolium salts in a reagent |
DE69328182T2 (en) | 1992-07-02 | 2000-09-28 | Roche Diagnostics Corp | REAGENT STABILIZED BY TWO-VALUE METAL SALTS |
DE4311464A1 (en) * | 1993-04-08 | 1994-10-13 | Boehringer Mannheim Gmbh | Method for the colorimetric determination of an analyte with a PQQ-dependent dehydrogenase |
JP2757348B2 (en) | 1996-04-18 | 1998-05-25 | 株式会社同仁化学研究所 | New water-soluble tetrazolium salt compound |
US6656697B1 (en) * | 1998-09-28 | 2003-12-02 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
US6420128B1 (en) * | 2000-09-12 | 2002-07-16 | Lifescan, Inc. | Test strips for detecting the presence of a reduced cofactor in a sample and method for using the same |
-
2000
- 2000-09-12 US US09/659,938 patent/US6420128B1/en not_active Expired - Lifetime
-
2001
- 2001-09-07 MX MXPA03002078A patent/MXPA03002078A/en unknown
- 2001-09-07 EP EP01968705A patent/EP1317563B1/en not_active Expired - Lifetime
- 2001-09-07 RU RU2003106573/13A patent/RU2288273C2/en not_active IP Right Cessation
- 2001-09-07 CN CNA018187099A patent/CN1561397A/en active Pending
- 2001-09-07 CA CA002422010A patent/CA2422010A1/en not_active Abandoned
- 2001-09-07 DE DE60115261T patent/DE60115261T2/en not_active Expired - Lifetime
- 2001-09-07 AU AU8893501A patent/AU8893501A/en not_active Withdrawn
- 2001-09-07 CZ CZ2003705A patent/CZ2003705A3/en unknown
- 2001-09-07 DK DK01968705T patent/DK1317563T3/en active
- 2001-09-07 WO PCT/US2001/028169 patent/WO2002022855A2/en active IP Right Grant
- 2001-09-07 AT AT01968705T patent/ATE310832T1/en active
- 2001-09-07 PL PL01363222A patent/PL363222A1/en not_active Application Discontinuation
- 2001-09-07 KR KR10-2003-7003589A patent/KR20030065475A/en not_active Application Discontinuation
- 2001-09-07 IL IL15471301A patent/IL154713A0/en unknown
- 2001-09-07 ES ES01968705T patent/ES2250472T3/en not_active Expired - Lifetime
- 2001-09-07 JP JP2002527297A patent/JP2004509618A/en active Pending
- 2001-09-10 MY MYPI20014239A patent/MY119106A/en unknown
- 2001-09-11 AR ARP010104288A patent/AR030650A1/en unknown
-
2002
- 2002-03-06 US US10/092,836 patent/US20020132282A1/en not_active Abandoned
-
2003
- 2003-03-11 NO NO20031116A patent/NO20031116L/en not_active Application Discontinuation
- 2003-08-28 HK HK03106177A patent/HK1053856A1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5902731A (en) * | 1998-09-28 | 1999-05-11 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch, Week 198512 Derwent Publications Ltd., London, GB; Class B04, AN 1985-070861 XP002198080 -& JP 60 024199 A (NIPPON CHEMIPHAR CO), 6 February 1985 (1985-02-06) * |
SOCK J ET AL: "ACTIVITY STAINING OF BLOTTED ENZYMES BY REACTION COUPLING WITH TRANSFER MEMBRANE-IMMOBILIZED AUXILLARY ENZYMES" ANALYTICAL BIOCHEMISTRY, vol. 171, no. 2, 1988, pages 310-319, XP008003063 ISSN: 0003-2697 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8287703B2 (en) | 1999-10-04 | 2012-10-16 | Roche Diagnostics Operations, Inc. | Biosensor and method of making |
US8551308B2 (en) | 1999-10-04 | 2013-10-08 | Roche Diagnostics Operations, Inc. | Biosensor and method of making |
US8298828B2 (en) | 2003-06-20 | 2012-10-30 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
US8071030B2 (en) | 2003-06-20 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Test strip with flared sample receiving chamber |
US8119414B2 (en) | 2003-06-20 | 2012-02-21 | Roche Diagnostics Operations, Inc. | Test strip with slot vent opening |
US8142721B2 (en) | 2003-06-20 | 2012-03-27 | Roche Diagnostics Operations, Inc. | Test strip with slot vent opening |
US8211379B2 (en) | 2003-06-20 | 2012-07-03 | Roche Diagnostics Operations, Inc. | Test strip with slot vent opening |
US8222044B2 (en) | 2003-06-20 | 2012-07-17 | Roche Diagnostics Operations, Inc. | Test strip with flared sample receiving chamber |
US7829023B2 (en) | 2003-06-20 | 2010-11-09 | Roche Diagnostics Operations, Inc. | Test strip with vent opening |
US7727467B2 (en) | 2003-06-20 | 2010-06-01 | Roche Diagnostics Operations, Inc. | Reagent stripe for test strip |
US7879618B2 (en) | 2003-06-20 | 2011-02-01 | Roche Diagnostics Operations, Inc. | Method and reagent for producing narrow, homogenous reagent strips |
US7749437B2 (en) | 2003-06-20 | 2010-07-06 | Roche Diagnostics Operations, Inc. | Method and reagent for producing narrow, homogenous reagent stripes |
US8586373B2 (en) | 2003-06-20 | 2013-11-19 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
US8663442B2 (en) | 2003-06-20 | 2014-03-04 | Roche Diagnostics Operations, Inc. | System and method for analyte measurement using dose sufficiency electrodes |
US9410915B2 (en) | 2004-06-18 | 2016-08-09 | Roche Operations Ltd. | System and method for quality assurance of a biosensor test strip |
WO2013016200A1 (en) * | 2011-07-22 | 2013-01-31 | Access Bio, Inc. | A single-pad strip for an improved lateral flow assay and a test device using the same |
CN103842523A (en) * | 2011-07-22 | 2014-06-04 | 阿赛斯生物股份有限公司 | A single-pad strip for an improved lateral flow assay and a test device using the same |
US9575056B2 (en) | 2011-07-22 | 2017-02-21 | Access Bio, Inc. | Single-pad strip for an improved lateral flow assay and a test device using the same |
KR101751205B1 (en) | 2011-07-22 | 2017-06-27 | 액세스 바이오 인코포레이티드 | A single-pad strip for an improved lateral flow assay and a test device using the same |
US10048251B2 (en) * | 2011-07-22 | 2018-08-14 | Access Bio, Inc. | Single-pad strip for an improved lateral flow assay and a test device using the same |
WO2018101525A1 (en) * | 2016-12-02 | 2018-06-07 | 에스디 바이오센서 주식회사 | Strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, manufacturing method therefor, and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2004509618A (en) | 2004-04-02 |
KR20030065475A (en) | 2003-08-06 |
NO20031116L (en) | 2003-05-09 |
PL363222A1 (en) | 2004-11-15 |
NO20031116D0 (en) | 2003-03-11 |
RU2288273C2 (en) | 2006-11-27 |
MXPA03002078A (en) | 2003-06-24 |
CZ2003705A3 (en) | 2004-01-14 |
DK1317563T3 (en) | 2006-03-20 |
WO2002022855A3 (en) | 2002-07-18 |
US6420128B1 (en) | 2002-07-16 |
AR030650A1 (en) | 2003-08-27 |
CN1561397A (en) | 2005-01-05 |
DE60115261D1 (en) | 2005-12-29 |
DE60115261T2 (en) | 2006-07-27 |
MY119106A (en) | 2005-03-31 |
AU8893501A (en) | 2002-03-26 |
ATE310832T1 (en) | 2005-12-15 |
EP1317563B1 (en) | 2005-11-23 |
IL154713A0 (en) | 2003-10-31 |
ES2250472T3 (en) | 2006-04-16 |
US20020132282A1 (en) | 2002-09-19 |
HK1053856A1 (en) | 2003-11-07 |
CA2422010A1 (en) | 2002-03-21 |
EP1317563A2 (en) | 2003-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6420128B1 (en) | Test strips for detecting the presence of a reduced cofactor in a sample and method for using the same | |
US6586199B2 (en) | Stabilized tetrazolium reagent compositions and methods for using the same | |
US6939685B2 (en) | Stabilized tetrazolium phenazine reagent compositions and methods for using the same | |
AU763065B2 (en) | Diagnostics based on tetrazolium compounds | |
US20040121423A1 (en) | Compositions containing a urea derivative dye for detecting an analyte and methods for using the same | |
CN103305590A (en) | Size self-limiting compositions and test devices for measuring analytes in biological fluids | |
RU2266543C2 (en) | Reagent systems for detecting for reduced cofactor | |
AU2001288935A2 (en) | Test-strips with positively charged membranes for tetrazolium based assays | |
JPH11253193A (en) | Test piece for assaying creatine kinase activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001288935 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 154713 Country of ref document: IL Ref document number: 267/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/002078 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2422010 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2003106573 Country of ref document: RU Kind code of ref document: A Ref country code: RU Ref document number: RU A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001968705 Country of ref document: EP Ref document number: PV2003-705 Country of ref document: CZ Ref document number: 1020037003589 Country of ref document: KR Ref document number: 2002527297 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018187099 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001968705 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037003589 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-705 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001968705 Country of ref document: EP |